Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
QCOR > SEC Filings for QCOR > Form 8-K on 18-Jan-2013All Recent SEC Filings

Show all filings for QUESTCOR PHARMACEUTICALS INC | Request a Trial to NEW EDGAR Online Pro

Form 8-K for QUESTCOR PHARMACEUTICALS INC


18-Jan-2013

Completion of Acquisition or Disposition of Assets, Financial Statem


Item 2.01 Completion of Acquisition or Disposition of Assets.

On January 4, 2013, Questcor Pharmaceuticals, Inc. ("Questcor") filed a Current Report on Form 8-K disclosing that on January 2, 2013, Questcor and its wholly owned subsidiary ("Acquisition Co."), entered into a Share Purchase Agreement (the "Agreement") to acquire all of the issued and outstanding shares of BioVectra Inc. ("BioVectra"). The purchase price consists of approximately C$50.0 million in cash at the closing plus up to an additional C$50.0 million in cash tied to the future performance of BioVectra.

Located in Prince Edward Island, Canada, BioVectra is a manufacturer to many of the pharmaceutical industry's leading pharmaceutical companies. BioVectra manufactures the active pharmaceutical ingredient in Questcor's H.P. ActharŽ Gel (repository corticotropin injection).

On January 18, 2013, Questcor and the other parties to the Agreement closed the transaction and BioVectra became a wholly-owned subsidiary of Acquisition Co.

The description of the Agreement included in the Current Report on Form 8-K filed on January 4, 2013 is hereby incorporated by reference. Such description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the Agreement, which will be filed as an exhibit to Questcor's Annual Report on Form 10-K for the year ended December 31, 2012.



Item 9.01 Financial Statements and Exhibits.

(a) Financial Statements of Business Acquired.

BioVectra's audited financial statements as of and for the year ended August 31, 2012 will be filed by amendment to this Current Report within 71 calendar days after the date this Current Report on Form 8-K is required to be filed.

BioVectra's unaudited financial statements as of and for the three months ended November 30, 2012 and November 30, 2011, respectively, will be filed by amendment to this Current Report within 71 calendar days after the date this Current Report on Form 8-K is required to be filed.

(b) Pro Forma Financial Information.

Pro forma financial information will be filed by amendment to this Current Report within 71 calendar days after the date this Current Report on Form 8-K is required to be filed.


  Add QCOR to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for QCOR - All Recent SEC Filings
Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial      Sign Up Now


Copyright © 2013 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.